Business
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticip
About this update from Bioage Labs, Inc.
[{"type":"image","alt":"BioAge Labs, Inc.","displaySize":"","headline":null,"caption":"BioAge Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q4VL90BcRUw5eG_L017gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0","width":300,"height":300}},"lazy":false},{"type":"text","content":"BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing","length":123,"tagName":"p"},{"type":"text","content":"Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14","length":122,"tagName":"p"},{"type":"text","content":"High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14","length":124,"tagName":"p"},{"type":"text","content":"Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026","length":154,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced positive interim data from the ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients with cardiovascular risk factors.","length":586,"tagName":"p"},{"type":"text","content":"“We’re very encouraged by the interim data from our ongoing Phase 1 trial of BGE-102, an NLRP3 inhibitor with best-in-class potential. Once-daily doses of 60 mg and above were well tolerated and exceeded target IC90 levels in both the periphery and the brain,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “The clear evidence of high brain penetration is especially important, as it supports BGE-102’s potential to comprehensively target NLRP3...